Solventum Corporation $SOLV Holdings Decreased by Nuance Investments LLC

Nuance Investments LLC decreased its holdings in shares of Solventum Corporation (NYSE:SOLV) by 7.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 642,073 shares of the company’s stock after selling 54,894 shares during the quarter. Solventum accounts for approximately 5.6% of Nuance Investments LLC’s holdings, making the stock its 6th biggest position. Nuance Investments LLC owned approximately 0.37% of Solventum worth $50,878,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Measured Wealth Private Client Group LLC purchased a new position in shares of Solventum during the third quarter valued at $25,000. Hilltop National Bank grew its holdings in shares of Solventum by 71.3% during the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after buying an additional 129 shares in the last quarter. JNBA Financial Advisors grew its holdings in shares of Solventum by 205.4% during the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after buying an additional 228 shares in the last quarter. CYBER HORNET ETFs LLC purchased a new position in shares of Solventum during the second quarter valued at $28,000. Finally, City State Bank grew its holdings in shares of Solventum by 166.7% during the fourth quarter. City State Bank now owns 384 shares of the company’s stock valued at $30,000 after buying an additional 240 shares in the last quarter.

Insiders Place Their Bets

In related news, Director Amy Mcbride Wendell bought 1,475 shares of Solventum stock in a transaction that occurred on Tuesday, March 10th. The stock was purchased at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the acquisition, the director owned 5,039 shares in the company, valued at $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.24% of the company’s stock.

Solventum Stock Down 1.6%

SOLV opened at $81.07 on Friday. The business has a 50 day moving average price of $70.91 and a 200 day moving average price of $75.21. Solventum Corporation has a twelve month low of $62.38 and a twelve month high of $88.20. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. The firm has a market cap of $14.04 billion, a P/E ratio of 9.93, a price-to-earnings-growth ratio of 1.27 and a beta of 0.69.

Solventum (NYSE:SOLV) last posted its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same period in the previous year, the company earned $1.34 EPS. The company’s revenue for the quarter was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Research analysts forecast that Solventum Corporation will post 6.58 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on SOLV shares. Wells Fargo & Company lowered their price target on Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 6th. BTIG Research reaffirmed a “buy” rating and issued a $89.00 target price on shares of Solventum in a research report on Wednesday, May 6th. Wall Street Zen lowered Solventum from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Piper Sandler dropped their target price on Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Finally, Stifel Nicolaus dropped their target price on Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Eight research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $84.25.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.